A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

A Single Center, Single Ascending Dose, Double-Blind, Randomized, Placebo-Controlled Trial to Establish Safety and the Maximum Tolerated Dose of Intravenous Trehalose Solution in Healthy Subjects

This will be a double-blind, randomized, placebo-controlled, single ascending dose study performed in healthy subjects.

The study will include up to four escalating dose cohorts with eight (8) subjects in each cohort.

In each cohort, eligible subjects will be randomized in a 3:1 ratio to receive single IV administration of 9% trehalose (Treatment Arm 1) or placebo (Treatment Arm 2).

All subjects, regardless of their treatment arm assignment, will undergo the same evaluations and will receive the study drug at the clinic. Each subject will continue to be followed for one week post dosing.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteer Subjects
• Intervention / Treatment: Drug: Trehalose for IV Infusion; Drug: Saline 0.9% IV

Detailed Description

This is a double-blind, randomized, placebo-controlled, single ascending dose study performed in healthy subjects.

The study will include up to four escalating dose cohorts with eight (8) subjects in each cohort.

In each cohort, eligible subjects will be randomized in a 3:1 ratio to receive single IV administration of 9% trehalose (Treatment Arm 1) or placebo (Treatment Arm 2).

All subjects, regardless of their treatment arm assignment, will undergo the same evaluations and will receive the study drug at the clinic. Each subject will continue to be followed for one week post dosing.

Cohorts 1 to 3 After all subjects in a given cohort complete their 1-week follow-up visit (Visit 4), a Safety Review Committee (SRC) will review the safety and PK data of that cohort. If no safety concerns are identified, and the exposure data supports a higher dose is acceptable, the SRC will approve continuation into the next cohort (dose level).

Cohort 4 Cohort 4 will be initiated based on review of the safety and exposure data from the first 3 cohorts by the SRC. This cohort will only be performed if there is a suggestion that exposure can be safely increased.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21225
      • PAREXEL Baltimore Early Phase Clinical Unit; Harbor Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 51 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy men and women between 18 and 55 years (inclusive) of age
2. Body Mass Index (BMI) 19 to 29.9 kg/m2 (inclusive) and weighing at least 55 kg.
3. Subjects in general good health in the opinion of the investigator
4. Blood pressure and heart rate within normal limits
5. Female subjects must have a negative serum pregnancy test during the Screening period (Day -28 to -1) and be willing and able to use a medically acceptable method of birth control or be postmenopausal.

Exclusion Criteria:

1. Diabetes mellitus type 1 or 2 or HbA1c > 5.6 % at Screening
2. History of significant medical disorder
3. Any clinically significant abnormality in safety laboratory tests during the Screening period (Day -28 to -1)
4. Known contraindication, hypersensitivity and/or allergy to trehalose
5. Any acute illness (e.g. acute infection) within 72 hours
6. Participation in another clinical trial with drugs received within 3 months prior to dosing
7. Positive serum pregnancy test determined during the Screening period or currently lactating women
8. ECG with clinically significant finding recorded during the Screening period
9. Positive HIV, Hepatitis B or Hepatitis C serology at Screening
10. Known history of alcohol or drug abuse in the past 5 years
11. Positive urinary drug screen determined during the Screening period

Study Plan

How is the study designed?

Design Details

• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Trehalose 9%; Single dose administration of Trehalose 9% for IV infusion.	Drug: Trehalose for IV Infusion
Placebo Comparator: Saline 0.9%; Single dose administration of 0.9% saline in the same volume and duration as Treatment Arm 1 (9% trehalose)	Drug: Saline 0.9% IV

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability of escalating doses of intravenously administered trehalose (incidence of adverse events and serious adverse events, including clinically significant laboratory abnormalities)	Safety will be assessed by the incidence of adverse events and serious adverse events, including clinically significant laboratory abnormalities.	Will be assessed during the entire study. At screening, at day -1 before drug administration, and day 1 of drug administration before, during and after drug administration, and at day 8 the follow up visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum-tolerated dose (MTD) of trehalose administered intravenously (Averse events, vitals signs)	The maximum-tolerated dose of trehalose will be assessed by evaluating the safety and tolerability of each of the escalating trehalose doses	Will be assessed during the entire study. At screening, at day -1 before drug administration, and day 1 of drug administration before, during and after drug administration, and at day 8 the follow up visit
Pharmacokinetics (PK) of plasma and urine trehalose	To determine the pharmacokinetics (PK) of trehalose following administration of escalating doses of trehalose	Will be assessed on the day of drug administration, before drug administration and up to 12hours following administration.
Pharmacokinetics (PK) of serum and urine glucose	To determine the pharmacokinetics (PK) of glucose following administration of escalating doses of trehalose	Will be assessed on the day of drug administration, before drug administration and up to 12hours following administration.

Collaborators and Investigators

• Sponsor: Bioblast Pharma Ltd.
• Collaborators: Parexel

Study record dates

Study Major Dates

• Study Start: March 1, 2016
• Primary Completion (Actual): June 1, 2016
• Study Completion (Actual): August 1, 2016

Study Registration Dates

• First Submitted: March 15, 2016
• First Submitted That Met QC Criteria: March 27, 2016
• First Posted (Estimate): April 1, 2016

Study Record Updates

• Last Update Posted (Estimate): November 22, 2016
• Last Update Submitted That Met QC Criteria: November 21, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Keywords: Bioblast
• Other Study ID Numbers: BB-TRE-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided